NuVasive has announced new executive leadership roles, with the appointments designed to strengthen the firm’s innovation and go-to-market teams while furthering the company’s growth.
Massimo Calafiore has been appointed chief commercial officer, and Ryan Donahoe has been appointed chief technology officer, with both reporting directly to CEO J. Christopher Barry.
“This new structure puts in place leaders who have decades of spine and orthopaedics experience to advance our near- and long-term strategy as we continue to globalise and scale our business,” said Barry. “I am confident Massimo’s and Ryan’s proven track records of building strong, effective teams and their commitment to our vision will help us deliver the strongest innovation pipeline in spine and increase value for our stakeholders.”
As chief commercial officer, Calafiore will oversee the product marketing, commercial, and commercial enablement functions, as well as NuVasive Specialised Orthopaedics and NuVasive Clinical Services.
Since joining the firm in 2017, Calafiore has held various leadership roles with increasing levels of responsibility, most recently serving as executive vice president, Global Business Units. Prior to NuVasive, he spent 16 years supporting and leading the US business for medical technology outfit, Waldemar Link.
As chief technology officer, Ryan Donahoe will continue to lead spine research and development. During his 15 years at NuVasive, Donahoe has been involved in shaping the company’s spine portfolio, with more than 20 issued and pending patents. He has helped develop technologies throughout NuVasive’s anterior, posterior, and cervical procedural offerings, along with the integration of the Pulse platform.
As well as the new appointments, NuVasive has also announced that Brent Boucher, executive vice president, Global Commercial, will “transition from the company”.
